Focused On-demand Library for Caveolae-associated protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6NZI2

UPID:

CAVN1_HUMAN

Alternative names:

Cavin-1; Polymerase I and transcript release factor

Alternative UPACC:

Q6NZI2; B2RAW7; O00535; Q6GMY1; Q96H74; Q9BT85; Q9HAP4

Background:

Caveolae-associated protein 1, also known as Cavin-1 and Polymerase I and transcript release factor, is pivotal in caveolae formation and organization across all tissues. It is a core component of the CAVIN complex, crucial for caveolae biogenesis in the presence of caveolin-1. Cavin-1 significantly influences ribosomal transcriptional activity in adipocytes and facilitates the formation of the ribosomal transcriptional loop. Its role extends to promoting the dissociation of transcription complexes, thereby enhancing RNA polymerase I and pre-RNA release.

Therapeutic significance:

Cavin-1's involvement in Congenital generalized lipodystrophy 4, characterized by lipodystrophy, muscular dystrophy, and cardiac anomalies, underscores its therapeutic potential. Understanding the role of Caveolae-associated protein 1 could open doors to potential therapeutic strategies for treating not only Congenital generalized lipodystrophy 4 but also other metabolic and muscular disorders.